Hong Kong expands histotripsy trials for kidney cancer amid commercial hype

Hong Kong hospitals, backed by the Li Ka Shing Foundation, are launching clinical trials of histotripsy for kidney cancer in 30 patients. The technology uses focused ultrasound to destroy tumors non-invasively, but evidence of efficacy remains preliminary. The expansion signals growing investment in the modality, though commercial claims may outpace clinical validation.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works